BNET Industries
Market Cap:$146.6B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
News & Analysis
Filter by
biotechnology and pfizer inc. and pharmaceutical company - All News and Analysis
Pfizer, Vertex Execs Are Victims of Facebook Faker; Forbes, WSJ Also Targeted
BNET
- 2009-04-29
Someone is impersonating prominent members of the pharma and biotech world on Facebook, including Vertex Pharmaceuticals chief executive Joshua Boger, a chief science officer at Pfizer and Forbes drug writer Matt Herper. by Jim Edwards
Pharma Roundup: Pfizer Re-Slices Organizational Pie, Lilly Dishes Out Zyprexa Settlement, and More
BNET
- 2008-10-07
Pfizer reorganizes; Lilly to pay $62 million fine over Zyprexa; biotech losing talent to clean tech; Consumer Reports blacklists 20 drugs for seniors by John Maas
Pharma's Deal-Making Frenzy: Lots of Noise, Less Substance
BNET
- 2008-09-11
Reading the mainstream press over the last few weeks could give you the strong impression that pharma has entered a phase of deal-making frenzy. Here's how Reuters describes it today: Big pharmaceutical companies are set to step up the hunt for assets to buy in promising fields like biotechnology,...
Good Medicine.(Biotech industry.)
- 2005-05-10
Byline: Steven Goldberg, Kiplinger Washington Editors Biotech is beginning to realize its potential -- for investors as well as patients. Meanwhile, pharmaceutical companies are continuing to struggle, although they will probably begin to see Byline: Steven Goldberg, Kiplinger...
Drug companies' hiring: Rx for city; Activity is one bright spot in bleak economy; biotech yet to take off.(News)
- 2003-01-27
Byline: mary sisson Dot-coms have come and gone. Wall Street has been slashing jobs with abandon. But in the midst of all that shrinkage, a surprising pocket of growth has opened up in the city's economy-hiring by pharmaceutical companies. Whil ...
Pfizer-Pharmacia fallout could be Rx for small firms.(laid-off scientists could fill slots at smaller new companies)(Brief Article)
- 2002-07-29
Historically, mergers of big pharmaceutical companies in Michigan have given life to small biotechnology companies when disgruntled or laid-off scientists left. Experts say Pfizer Inc.'s acquisition of Pharmacia Corp. is likely no exception. The h Historically, mergers of big pharmaceutical companies in Michigan...
Rx for the Bear-Market Blues.
- 2001-04-03
Byline:Steven Goldberg, Kiplinger Washington Editors With all the major averages in or near bear-market territory and Nasdaq at a two-and-a-half year low, where can an investor seek shelter? Many of the traditional "defensive stocks, ...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
